Shandong Weigao Group Medical Polymer Company Limited

SEHK:1066 Lagerbericht

Marktkapitalisierung: HK$27.4b

Shandong Weigao Group Medical Polymer Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Shandong Weigao Group Medical Polymer wird ein jährliches Gewinn- und Umsatzwachstum von 8.5% bzw. 7.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 8.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 9.4% betragen.

Wichtige Informationen

8.5%

Wachstumsrate der Gewinne

8.37%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum42.7%
Wachstumsrate der Einnahmen7.8%
Zukünftige Eigenkapitalrendite9.41%
Analystenabdeckung

Good

Zuletzt aktualisiert17 Apr 2025

Jüngste Aktualisierungen zum künftigen Wachstum

Analysts Are Updating Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Estimates After Its Annual Results

Mar 28
Analysts Are Updating Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Estimates After Its Annual Results

Analysts Have Been Trimming Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Price Target After Its Latest Report

Sep 24
Analysts Have Been Trimming Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Price Target After Its Latest Report

Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Just Reported, And Analysts Assigned A HK$6.74 Price Target

Aug 30
Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Just Reported, And Analysts Assigned A HK$6.74 Price Target

Analysts Have Lowered Expectations For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) After Its Latest Results

Mar 28
Analysts Have Lowered Expectations For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) After Its Latest Results

Recent updates

Shandong Weigao Group Medical Polymer (HKG:1066) Seems To Use Debt Rather Sparingly

May 06
Shandong Weigao Group Medical Polymer (HKG:1066) Seems To Use Debt Rather Sparingly

Analysts Are Updating Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Estimates After Its Annual Results

Mar 28
Analysts Are Updating Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Estimates After Its Annual Results

Pinning Down Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) P/E Is Difficult Right Now

Mar 10
Pinning Down Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) P/E Is Difficult Right Now

Shandong Weigao Group Medical Polymer (HKG:1066) Is Reinvesting At Lower Rates Of Return

Feb 07
Shandong Weigao Group Medical Polymer (HKG:1066) Is Reinvesting At Lower Rates Of Return

Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?

Nov 26
Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?

Be Wary Of Shandong Weigao Group Medical Polymer (HKG:1066) And Its Returns On Capital

Nov 04
Be Wary Of Shandong Weigao Group Medical Polymer (HKG:1066) And Its Returns On Capital

Analysts Have Been Trimming Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Price Target After Its Latest Report

Sep 24
Analysts Have Been Trimming Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Price Target After Its Latest Report

Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Just Reported, And Analysts Assigned A HK$6.74 Price Target

Aug 30
Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Just Reported, And Analysts Assigned A HK$6.74 Price Target

Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 27% Share Price Plunge Could Signal Some Risk

Jun 25
Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 27% Share Price Plunge Could Signal Some Risk

Here's What To Make Of Shandong Weigao Group Medical Polymer's (HKG:1066) Decelerating Rates Of Return

Jun 23
Here's What To Make Of Shandong Weigao Group Medical Polymer's (HKG:1066) Decelerating Rates Of Return

Shandong Weigao Group Medical Polymer's (HKG:1066) Shareholders Will Receive A Bigger Dividend Than Last Year

May 31
Shandong Weigao Group Medical Polymer's (HKG:1066) Shareholders Will Receive A Bigger Dividend Than Last Year

We Think Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) CEO Compensation Package Needs To Be Put Under A Microscope

May 22
We Think Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) CEO Compensation Package Needs To Be Put Under A Microscope

Earnings Not Telling The Story For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)

Apr 23
Earnings Not Telling The Story For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)

Analysts Have Lowered Expectations For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) After Its Latest Results

Mar 28
Analysts Have Lowered Expectations For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) After Its Latest Results

Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Shares May Have Run Too Fast Too Soon

Jan 09
Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Shares May Have Run Too Fast Too Soon

Returns On Capital Are Showing Encouraging Signs At Shandong Weigao Group Medical Polymer (HKG:1066)

Dec 22
Returns On Capital Are Showing Encouraging Signs At Shandong Weigao Group Medical Polymer (HKG:1066)

Are Investors Undervaluing Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) By 44%?

Nov 10
Are Investors Undervaluing Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) By 44%?

Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?

Oct 05
Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?

Return Trends At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Appealing

Aug 01
Return Trends At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Appealing

Is Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Trading At A 28% Discount?

Jul 19
Is Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Trading At A 28% Discount?

Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth

Jun 22
Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth

Is Shandong Weigao Group Medical Polymer (HKG:1066) Using Too Much Debt?

Jun 09
Is Shandong Weigao Group Medical Polymer (HKG:1066) Using Too Much Debt?

The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing

Apr 27
The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing

Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth

Mar 17
Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth

A Look At The Intrinsic Value Of Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)

Feb 27
A Look At The Intrinsic Value Of Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)

Returns On Capital At Shandong Weigao Group Medical Polymer (HKG:1066) Have Hit The Brakes

Jan 18
Returns On Capital At Shandong Weigao Group Medical Polymer (HKG:1066) Have Hit The Brakes

Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?

Dec 12
Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?

Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Shares Could Be 21% Below Their Intrinsic Value Estimate

Nov 29
Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Shares Could Be 21% Below Their Intrinsic Value Estimate

Here's Why We Think Shandong Weigao Group Medical Polymer (HKG:1066) Might Deserve Your Attention Today

Nov 14
Here's Why We Think Shandong Weigao Group Medical Polymer (HKG:1066) Might Deserve Your Attention Today

Shandong Weigao Group Medical Polymer (HKG:1066) Is Paying Out A Larger Dividend Than Last Year

Oct 03
Shandong Weigao Group Medical Polymer (HKG:1066) Is Paying Out A Larger Dividend Than Last Year

The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing

Sep 21
The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing

Shandong Weigao Group Medical Polymer (HKG:1066) Could Easily Take On More Debt

Sep 05
Shandong Weigao Group Medical Polymer (HKG:1066) Could Easily Take On More Debt

Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Intrinsic Value Is Potentially 27% Above Its Share Price

Aug 23
Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Intrinsic Value Is Potentially 27% Above Its Share Price

Here's Why Shandong Weigao Group Medical Polymer (HKG:1066) Has Caught The Eye Of Investors

Aug 08
Here's Why Shandong Weigao Group Medical Polymer (HKG:1066) Has Caught The Eye Of Investors

There's Been No Shortage Of Growth Recently For Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital

Jun 22
There's Been No Shortage Of Growth Recently For Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital

Shandong Weigao Group Medical Polymer (HKG:1066) Will Pay A Smaller Dividend Than Last Year

Jun 08
Shandong Weigao Group Medical Polymer (HKG:1066) Will Pay A Smaller Dividend Than Last Year

An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 27% Undervalued

May 16
An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 27% Undervalued

Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?

May 03
Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?

Gewinn- und Umsatzwachstumsprognosen

SEHK:1066 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/202716,5322,6652,8704,8395
12/31/202615,4462,4872,6112,6508
12/31/202514,2862,2872,2243,0218
12/31/202413,0872,0672,1442,790N/A
9/30/202413,0271,9892,0852,747N/A
6/30/202412,9671,9122,0182,704N/A
3/31/202413,0981,9572,0662,751N/A
12/31/202313,2292,0022,1202,799N/A
9/30/202313,3982,2211,6432,539N/A
6/30/202313,5662,4401,1662,280N/A
3/31/202313,6572,6021,1732,287N/A
12/31/202213,7472,7641,1812,295N/A
9/30/202213,9032,6761,4332,573N/A
6/30/202214,0582,5891,6852,852N/A
3/31/202213,6332,4321,8032,969N/A
12/31/202113,2092,2761,9203,087N/A
9/30/202112,9232,2882,0213,088N/A
6/30/202112,6362,3002,1213,089N/A
3/31/202112,1292,1941,9712,938N/A
12/31/202011,6222,0871,8212,788N/A
9/30/202011,1391,9981,5572,533N/A
6/30/202010,6561,9091,2922,277N/A
3/31/202010,5201,8791,3152,300N/A
12/31/201910,3841,8501,3372,322N/A
9/30/20199,9931,8051,4562,347N/A
6/30/20199,6021,7601,5752,371N/A
3/31/20199,2051,6161,5002,295N/A
12/31/20188,8091,4731,4242,219N/A
6/30/20187,4651,255N/A1,812N/A
3/31/20186,8791,255N/A1,539N/A
12/31/20176,2931,255N/A1,266N/A
6/30/20175,4021,297N/A1,233N/A
3/31/20175,5111,165N/A1,143N/A
12/31/20165,6201,033N/A1,053N/A
9/30/20166,4841,010N/A1,042N/A
6/30/20166,237914N/A1,030N/A
3/31/20166,0781,013N/A1,041N/A
12/31/20155,9191,113N/A1,053N/A
9/30/20155,8781,237N/AN/AN/A
6/30/20155,6101,196N/A622N/A
3/31/20155,5481,161N/AN/AN/A
12/31/20145,2781,085N/A711N/A
9/30/20145,011307N/AN/AN/A
6/30/20144,996431N/A794N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 1066Das prognostizierte Gewinnwachstum (8.5% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: 1066Die Erträge des Unternehmens (8.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Hong Kong (10.4% pro Jahr).

Hohe Wachstumserträge: 1066Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: 1066Die Einnahmen des Unternehmens (7.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Hong Kong (8.5% pro Jahr).

Hohe Wachstumseinnahmen: 1066Die Einnahmen des Unternehmens (7.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 1066Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (9.4%).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2025/05/14 09:47
Aktienkurs zum Tagesende2025/05/14 00:00
Gewinne2024/12/31
Jährliche Einnahmen2024/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Shandong Weigao Group Medical Polymer Company Limited wird von 33 Analysten beobachtet. 8 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Jason MannBarclays
Derrick SunBNP Paribas Securities (Asia)
Jessica LiBofA Global Research